Share on StockTwits

Harvard Bioscience (NASDAQ:HBIO) announced its earnings results on Thursday. The company reported $0.05 EPS for the quarter, meeting the Thomson Reuters consensus estimate of $0.05, AmericanBankingNews.com reports.

Shares of Harvard Bioscience (NASDAQ:HBIO) traded down 2.98% on Thursday, hitting $4.56. 77,761 shares of the company’s stock traded hands. Harvard Bioscience has a 1-year low of $3.68 and a 1-year high of $5.15. The stock’s 50-day moving average is $4.4 and its 200-day moving average is $4.41. The company’s market cap is $145.7 million. Harvard Bioscience also was the target of a significant drop in short interest in July. As of July 15th, there was short interest totalling 427,425 shares, a drop of 79.0% from the June 30th total of 2,039,971 shares. Based on an average daily volume of 164,239 shares, the short-interest ratio is currently 2.6 days. Approximately 1.6% of the shares of the stock are sold short.

Several analysts have recently commented on the stock. Analysts at Alere Financial initiated coverage on shares of Harvard Bioscience in a research note on Thursday, July 24th. They set a “buy” rating and a $8.00 price target on the stock. On the ratings front, analysts at Zacks downgraded shares of Harvard Bioscience to a “neutral” rating in a research note on Tuesday, July 1st. They now have a $4.80 price target on the stock. Finally, analysts at Janney Montgomery Scott initiated coverage on shares of Harvard Bioscience in a research note on Wednesday, June 25th. They set a “buy” rating and a $9.00 price target on the stock.

Harvard Bioscience, Inc is a global developer, manufacturer and marketer of a range of specialized products, apparatus and scientific instruments, used to advance life science research at pharmaceutical and biotechnology companies, universities and government laboratories worldwide.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.